Helix BioPharma Abandons GEM Financing Deal After Strategic Review
Helix BioPharma has decided against proceeding with a previously announced equity financing facility with GEM, citing misalignment with its capital strategy and commitment to shareholder value, while continuing to explore alternative funding options for its oncology pipeline.
Helix BioPharma Corp. has elected not to proceed with a previously announced equity draw-down subscription facility with GEM Global Yield LLC SCS and GEM Yield Bahamas Limited. The clinical-stage oncology company, which is shaping a near future where today's hard-to-treat cancers are vincible, made this decision following a thorough evaluation of market conditions and long-term corporate objectives.
The company had entered into a non-binding term sheet with GEM dated October 15, 2024, and disclosed the proposed subscription facility in news releases dated February 24, 2025 and March 26, 2025, as well as in the company's Management and Information Circular dated January 31, 2025. Shareholders had approved the financing arrangement at the company's annual general and special meeting on March 26, 2025, as detailed in the voting results announcement.
However, Helix determined that the GEM facility no longer aligns with its capital strategy or its commitment to maximizing long-term shareholder value. The letter of intent expired in accordance with its terms, and the company has chosen not to proceed to execution of binding agreements or pursue the financing with GEM. This decision reflects the company's strategic reassessment of financing options in light of current market dynamics.
Independently of this decision, Helix continues to engage in constructive discussions with financial partners to explore alternative financing structures that may better align with the company's needs and strategic direction. The company remains steadfast in its commitment to securing the capital required to advance its clinical programs and achieve its corporate objectives. The company had previously extended the date of its annual meeting to seek approval for asset acquisitions and proposed financing, as noted in the announcement regarding the meeting extension.
This development is significant for investors and the biopharmaceutical sector as it demonstrates Helix's proactive approach to capital management and strategic alignment. The decision to walk away from a shareholder-approved financing arrangement indicates the company's confidence in exploring better alternatives that support its oncology pipeline development while maintaining focus on long-term value creation for stakeholders.